Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN12140 in Adults With Primary IgA Nephropathy
CTR20260120Phase 2Active
- Sponsor
- Linnuo Pharma
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SLN12140 in IgA nephropathy (IgAN), sponsored by Linnuo Pharma. Started Jan 2026; status: active.
02
Drugs
SLN12140
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260120.